Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 222Liver Neoplasms 68Neoplasms 18Pancreatic Neoplasms 16Neoplasm Metastasis 14Colorectal Neoplasms 12Rectal Neoplasms 8Stomach Neoplasms 7Colonic Neoplasms 7Carcinoma, Renal Cell 6Carcinoma 6Liver Diseases 5Gallbladder Neoplasms 5Breast Neoplasms 5Digestive System Neoplasms 4Bile Duct Neoplasms 4Prostatic Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Adenocarcinoma 3Neoplasms, Glandular and Epithelial 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Melanoma 2Hepatoblastoma 2Hepatitis C 2Hepatitis B 2Hematologic Neoplasms 2Glioblastoma 2

Interventions

pembrolizumab 1enzalutamide 1bintrafusp alfa protein, human 1Sorafenib 1LY-2157299 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × Sorafenib × Gastrointestinal × Clear all
NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡